Tazemetostat (TAZVERIK®), an epigenetic therapy for non-Hodgkin lymphoma (NHL), needed a diagnostic tool to identify mutations in the EZH2 gene. This evidence concerns the gene EZH2 and non-Hodgkin lymphoma.